Upregulation of striatal preproenkephalin gene expression occurs before the appearance of Parkinsonian signs in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys

Neurobiology of Disease

Volumn 8, Issue 2, 2001, Pages 343-350

  Bezard, E ^a   Ravenscroft, P ^a   Gross, C E ^b   Crossman, A R ^a   Brotchie, J M ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 4 AMINOBUTYRIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BASAL GANGLION; CONTROLLED STUDY; DISEASE COURSE; DOPAMINERGIC SYSTEM; FEMALE; GENE CONTROL; GLOBUS PALLIDUS; HISTOCHEMISTRY; MONKEY; MOTOR DYSFUNCTION; NERVE CELL NECROSIS; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; STRIATE CORTEX;

EID: 0035029246     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1006/nbdi.2000.0375     Document Type: Article

References (39)

1. Parkinson's disease: Pathophysiology
2. Functional architecture of basal ganglia circuits: Neural substrates of parallel processing
3. Striatal changes in preproenkephalin mRNA levels in parkinsonian monkeys
4. Parkinsonian-like locomotor impairment in mice lacking dopamine D2 receptors
5. Compensatory effects of glutamatergic inputs to the substantia nigra pars compacta in experimental parkinsonism
6. Involvement of the subthalamic nucleus in glutamatergic compensatory mechanisms
7. Evolution of the multiunit activity of basal ganglia in the course of a dynamic experimental parkinsonism
8. Presymptomatic revelation of experimental parkinsonism
9. A chronic MPTP model reproducing the slow evolution of Parkinson's disease: Evolution of motor symptoms in the monkey
10. Primate models of movement disorders of basal ganglia origin
11. Topographical organization of opioid peptide precursor gene expression following repeated apomorphine treatment in the 6-hydroxydopamine-lesioned rat
12. Verteilung von Noradrenalin und Dopamin (3-Hydroxytyramin) im Gehirn des Menschen und ihr Verhalten bei Erkrankungen des extrapyramidalen Systems
13. Terminal excitability of the corticostriatal pathway. I. Regulation by dopamine receptor stimulation
14. 2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons
15. Preproenkephalin mRNA and methionine-enkephalin increase in mouse striatum after 1-methyl-1,2,3,6-tetrahydropyridine treatment
16. Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat
17. Effects of L-Dopa on preproenkephalin and preprotachykinin gene expression in the MPTP-treated monkey striatum
18. Consequence of nigrostriatal denervation and L-dopa therapy on the expression of glutamic acid decarboxylase messenger RNA in the pallidum
19. A new chronic MPTP model: Validation in monkey and mouse
20. Impaired activation of the supplementary motor area in Parkinson's disease is reversed when akinesia is treated with apomorphine
21. Re-evaluation of the functional anatomy of the basal ganglia in normal and parkinsonian states
22. 67-mRNA
23. On the role of enkephalin cotransmission in the GABAergic striatal efferents to the Globus Pallidus
24. Neural mechanisms underlying parkinsonian symptoms based upon regional uptake of 2-deoxyglucose in monkeys exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
25. Differential regulation of striatal preproenkephalin and preprotachykinin mRNA levels in MPTP-lesioned monkeys chronically treated with dopamine D-1 or D-2 receptor agonists
26. Preproenkephalin and preprotatachykinin messenger RNA expression in normal basal ganglia and in Parkinson's disease
27. Temporal dissociation between changes in striatal enkephalin and substance P messenger RNAs following striatal dopamine depletion
28. Local cerebral glucose utilization in monkeys with hemiparkinsonism induced by intracarotid infusion of the neurotoxin MPTP
29. Functional anatomy of the basal ganglia. I. The cortico-basal ganglia-thalamo-cortical loop
30. Impaired activation of frontal areas during movement in Parkinson's disease: A PET study
31. Cortical motor overactivation in parkinsonian patients with L-dopa-induced peak-dose dyskinesia
32. Supplementary and primary sensory motor area activity in Parkinson's disease: Regional cerebral blood flow changes during finger movements and effects of apomorphine
33. Paradoxical increases in striatal neuropeptide gene expression following ischemic lesion of the cerebral cortex
34. Striatal preproenkephalin gene expression is upregulated in acute but not chronic parkinsonian monkeys: Implications for the contribution of the indirect striatopallidal circuit to parkinsonian symptomatolology
35. Dopamine-releasing action of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 1-methyl-4-phenylpyridine (MPP+) in the neostriatum of the rat as demonstrated in vivo by the pushpull perfusion technique: Dependence on sodium but not calcium ions
36. Glutamate decarboxylase (GAD67 and GAD65) gene expression is increased in a subpopulation of neurons in the putamen of parkinsonian monkeys
37. Behavioral effects of MPTP administration in the Vervet monkey, a primate model of Parkinson's disease
38. Differential expression of preproenkephalin and preprodynorphin mRNAs in striatal neurons: High levels of preproenkephalin expression depend on cerebral cortical afferents
39. Consequences of nigrostriatal denervation on the functioning of the basal ganglia in human and nonhuman primates: An in situ hybridization study of cytochrome oxidase subunit I mRNA